Healthcare Business

analysis

Sanofi Just Can’t Catch a Break, Knocking at Major Support Again

Investor sentiment surrounding French pharma giant Sanofi S.A. (NYSE: SNY) continues to sour after a string of disappointing news in recent months has brought its shares down below the key ...
Read Full Story »
Prescription drugs

Major Pharma Short Interest Faces Significant Drop

The short interest data have been released for the August 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
biotech word cloud

Short Sellers Increase Bets in Major Biotechs

The short interest data are out for the August 15 settlement date. Companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big ...
Read Full Story »
road fork sign

Concerns Persist on Mylan EpiPen Price Gouging — or Do They?

Mylan N.V. (NASDAQ: MYL) has been controversial for some time now. As a top player in the world of generics and having brand drugs, it should be in a great place. ...
Read Full Story »
thumbs up

How Analysts and Investors Are Chasing Clovis Higher and Higher, All Over Again

Clovis Oncology Inc. (NASDAQ: CLVS) posted a massive gain of 27% to $23.03 on Tuesday, on the heels of news that the Food and Drug Administration (FDA) had granted it ...
Read Full Story »
mosquito

Federal Funding Approved for Rapid Zika Virus Test

Medical diagnostics maker OraSure Technologies Inc. (NASDAQ: OSUR) said Tuesday night that it has been awarded a $16.6 million contract to proceed with work on the company's rapid tests for ...
Read Full Story »
Female patient on gurney

How Clovis Scored Big on a Milestone FDA Approval

Clovis Oncology, Inc. (NASDAQ: CLVS) is watching its shares climb late Tuesday after the company announced a key U.S. Food and Drug Administration (FDA) approval. Note that this is the ...
Read Full Story »
graph

Valeant Gains Momentum With New CFO Appointment

Shares of Valeant Pharmaceuticals International Inc. (NYSE: VRX) saw a handy gain in Monday’s session after the company announced that it has appointed a new chief financial officer (CFO). Considering the ...
Read Full Story »
Prescription drugs

Pfizer Pays a Big Premium for Medivation

In one of the longest running bidding wars in recent times, Pfizer Inc. (NYSE: PFE) has finally reeled in cancer-drug maker Medivation Inc. (NASDAQ: MDVN) for a whopping $81.50 a ...
Read Full Story »
money

How Much Medivation Can Really Fetch in a Buyout

Medivation Inc. (NASDAQ: MDVN) has been among the top future biotech mergers for quite some time. The problem is that we still have no idea which company will buy Medivation, ...
Read Full Story »
Female patient on gurney

Thursday’s Top Health Care Stocks Punishing Investors

On Thursday, a few companies in the biotech and pharmaceutical industries made substantial runs. In this case it was all downward, due to the results of U.S. Food and Drug ...
Read Full Story »
choose happiness

Why Valeant Got Its First Big Analyst Upgrade of 2016

Valeant Pharmaceuticals International Inc. (NYSE: VRX) has been on the rise in the past month on increasingly positive news surrounding the company’s position. It seems like Joe Papa’s involvement as ...
Read Full Story »
Medicine pills

Tuesday’s Top Health Care Movers

On Tuesday, a few biotech companies made substantial runs, either up and down, due to the results of U.S. Food and Drug Administration (FDA) approvals, failed or passed trials and ...
Read Full Story »
thumbs up

Why Every Analyst in the World Loves Patheon Even After a Strong IPO

Patheon N.V. (NYSE: PTHN) saw its quiet period come to an end on Monday, and the analyst floodgates opened wide. Many calls were made on Monday, but Tuesday brought follow-on ...
Read Full Story »
graph

Can Eleven Biotherapeutics Keep Climbing With This Roche Deal?

Eleven Biotherapeutics Inc. (NASDAQ: EBIO) has been on an absolute rampage in 2016. In just the past quarter alone the stock has practically quadrupled. For an idea of how much ...
Read Full Story »